Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.…
Inogen, Inc. Q3 2026 Earnings Call Summary
Inogen (NASDAQ: INGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 753 employees.
The shares were at 5.300 USD on 20 November 2026, down 24.2% over 52 weeks. Its 52-week range is 5.045 USD to 7.670 USD: the price is 30.9% below the high and 5.1% above the low.
Its market capitalisation is 137.81M USD.
Inogen reports return on equity of -11.8%, an operating margin of -8.1% and revenue down 2.4% year over year.
It holds more cash than debt, a net cash position of 81.91M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 10.75 USD is 102.8% above the current price. The next earnings report is expected on 23 February 2027.